Allarity Therapeutics, Inc. 8-K

What Happened

• On April 27, 2026, Allarity Therapeutics, Inc. announced that the U.S. Patent and Trademark Office (USPTO) issued a Notice of Allowance for the company’s patent application covering its DRP® companion diagnostic specific to stenoparib. The company filed a press release about the announcement as Exhibit 99.1 to its Form 8-K (filed April 28, 2026).

Key Details

• Date of announcement: April 27, 2026.
• Issuing authority: United States Patent and Trademark Office (USPTO) issued a Notice of Allowance.
• Subject: Patent application covering Allarity’s DRP® companion diagnostic specific to the drug stenoparib.
• Disclosure: Company press release is included as Exhibit 99.1 to the Form 8-K.

Why It Matters

• A USPTO Notice of Allowance indicates the office has approved the claims in the application and intends to grant a patent, subject to completion of formal requirements. For investors, this is a concrete step toward formal intellectual property protection for Allarity’s diagnostic tied to stenoparib, which can affect the company’s ability to commercialize or partner around that diagnostic. The 8-K provides official public notice of the development and the related press release.